keyword
MENU ▼
Read by QxMD icon Read
search

Plaque psoriasis

keyword
https://www.readbyqxmd.com/read/28815560/comparison-of-indirubin-concentrations-in-indigo-naturalis-ointment-for-psoriasis-treatment-a-randomized-double-blind-dosage-controlled-trial
#1
Y K Lin, L C See, Y H Huang, C C Chi, R C Y Hui
BACKGROUND: Indigo naturalis and its refined formulation, Lindioil, are effective in treating psoriatic symptoms topically. Indirubin is the active ingredient in indigo naturalis. OBJECTIVES: To determine the efficacy and safety of different concentrations of indirubin in Lindioil ointment for treating psoriasis. METHODS: In this randomized, double-blind trial, adult patients presenting with chronic plaque psoriasis for >1 year and with <20% of the body surface area (BSA) affected were randomized to apply Lindioil ointment containing 200 μg/g, 100 μg/g, 50 μg/g, or 10 μg/g of indirubin twice daily for 8 weeks followed by an additional 12-week safety/extension period...
August 17, 2017: British Journal of Dermatology
https://www.readbyqxmd.com/read/28815476/long-term-safety-and-effectiveness-of-adalimumab-for-moderate-to-severe-psoriasis-results-from-7-year-interim-analysis-of-the-esprit-registry
#2
Alan Menter, Diamant Thaçi, Jashin J Wu, William Abramovits, Francisco Kerdel, Dilek Arikan, Dianlin Guo, Arijit Ganguli, Mareike Bereswill, Anne Camez, Wendell C Valdecantos
INTRODUCTION: ESPRIT (NCT00799877) is an ongoing 10-year international prospective observational registry evaluating the long-term safety and effectiveness of originator adalimumab in routine clinical practice for adult patients with chronic plaque psoriasis. Herein, we report the long-term safety, effectiveness, and patient-reported outcomes (PROs) following adalimumab treatment over the first 7 years of the ESPRIT registry. METHODS: All treatment-emergent (All-TE) adverse events (AE) since the initial (first ever) dose of adalimumab were assessed...
August 16, 2017: Dermatology and Therapy
https://www.readbyqxmd.com/read/28809995/efficacy-and-safety-of-apremilast-in-patients-with-moderate-plaque-psoriasis-with-lower-bsa-week-16-results-from-the-unveil-study
#3
Bruce Strober, Jerry Bagel, Mark Lebwohl, Linda Stein Gold, J Mark Jackson, Rongdean Chen, Joana Goncalves, Eugenia Levi, Kristina Callis Duffin
<p>INTRODUCTION: Many options are available for patients with moderate to severe plaque psoriasis. Patients with moderate disease, however, are often undertreated and do not achieve satisfactory clearance. UNVEIL (NCT02425826) assessed efficacy and safety of apremilast in patients with chronic moderate plaque psoriasis.</p> <p>METHODS: Patients with psoriasis body surface area (BSA) 5% to 10% and static Physician's Global Assessment (sPGA) score of 3 (moderate) without prior exposure to systemics were randomized (2:1) to apremilast 30 mg twice daily or placebo for 16 weeks...
August 1, 2017: Journal of Drugs in Dermatology: JDD
https://www.readbyqxmd.com/read/28809993/adalimumab-in-chronic-plaque-psoriasis-a-clinical-guide
#4
Jashin J Wu, W C Valdecantos
<p>Psoriasis is a common, inflammatory disease that manifests itself as lesions on the skin, which greatly impacts the physical and psychological wellbeing of those affected. The current goal of treatment in psoriasis is to improve the signs and symptoms of disease, whilst minimizing the burden of disease on patient health-related quality of life. Psoriasis can also be associated with other comorbidities such as joint disease, cardiovascular disease, and depression, which can add to the complexity of treatment...
August 1, 2017: Journal of Drugs in Dermatology: JDD
https://www.readbyqxmd.com/read/28809989/a-comparative-study-to-evaluate-epidermal-barrier-integrity-of-psoriasis-patients-treated-with-calcipotriene-betamethasone-topical-suspension-versus-betamethasone-dipropionate-0-05-lotion
#5
Peter W Hashim, John K Nia, David Terrano, Gary Goldenberg, Leon H Kircik
<p>BACKGROUND: Topical corticosteroids are known to impair the epidermal barrier, even after short-term use, whereas topical vitamin D analogues can have a reparative effect. Combination products using corticosteroids and vitamin D analogues have gained popularity in recent years and may provide a means to minimize skin atrophy in patients treated with topical corticosteroids.</p> <p>OBJECTIVE: To compare epidermal barrier function and cutaneous atrophy after 4 weeks of calcipotriene 0.005% and betamethasone dipropionate 0...
August 1, 2017: Journal of Drugs in Dermatology: JDD
https://www.readbyqxmd.com/read/28809988/methods-for-imputing-missing-efficacy-data-in-clinical-trials-of-biologic-psoriasis-therapies-implications-for-interpretations-of-trial-results
#6
Richard G B Langley, Kristian Reich, Charis Papavassilis, Todd Fox, Yankun Gong, Achim Gu Ttner
<p>BACKGROUND: An issue in long-term clinical trials of biologics in psoriasis is how to handle missing efficacy data. This methodological challenge may not be understood by clinicians, yet can have a significant effect on the interpretation of clinical trials.</p> <p>OBJECTIVE Evaluate the effects of different data imputation methods on apparent secukinumab response rates.</p> <p>METHODS: Post hoc analyses were conducted on efficacy data from 2 phase III, multicenter, randomized, double-blind trials (FIXTURE and ERASURE) of secukinumab in moderate to severe plaque psoriasis...
August 1, 2017: Journal of Drugs in Dermatology: JDD
https://www.readbyqxmd.com/read/28789577/utility-of-boron-in-dermatology
#7
David G Jackson, Leah A Cardwell, Elias Oussedik, Steven R Feldman
INTRODUCTION: Boron compounds are being investigated as therapies for dermatologic conditions. Several features of boron chemistry make this element an ideal component in dermatologic treatments. We review the published dermatologically-relevant clinical trials and case studies pertaining to boron compounds. METHODS: PubMed was utilized to query terms boron, chemistry, drug, development, dermatology, atopic dermatitis, psoriasis, onychomycosis, tavaborole, AN 2690, crisaborole, and AN 2728...
August 9, 2017: Journal of Dermatological Treatment
https://www.readbyqxmd.com/read/28782467/current-and-under-development-treatment-modalities-of-psoriasis-a-review
#8
Abdul Albaghdadi
BACKGROUND AND OBJECTIVE: Psoriasis is a chronic and complex autoimmune inflammatory skin disease that affects over 125 million people worldwide. It can exhibit at any age, in spite of the fact that children are less normally influenced than adults. It is characterized by distinct erythematous plaques shielded with conspicuous silvery scales that shows up in different areas of the skin. Knowledge of pathophysiology, especially the pathogenesis of psoriasis, has significantly progressed in the recent decade...
August 4, 2017: Endocrine, Metabolic & Immune Disorders Drug Targets
https://www.readbyqxmd.com/read/28780055/-amoxicillin-induced-skin-rash-sparing-a-plaque-of-erythema-migrans-renb%C3%A3-k-phenomenon-case-report-and-literature-review
#9
M Dumas, L Blum, E Begon
INTRODUCTION: Renbök phenomenon describes the inhibition of a lesion when a different one appears. We describe the first case of Renbök phenomenon occurring in a context of erythema migrans (EM) spared by an amoxicillin-induced skin rash and we also present a literature review. CASE REPORT: A 60-year-old patient was treated with amoxicillin for EM on the right knee and subsequently developed generalized erythema as a result of an antibiotic-induced skin rash, with sparing of the area previously affected by EM...
August 2, 2017: Annales de Dermatologie et de Vénéréologie
https://www.readbyqxmd.com/read/28763072/-diagn%C3%A3-stico-tard%C3%A3-o-de-psoriasis-motivos-y-consecuencias
#10
José Carlos Quiroz-Vergara, Martha Alejandra Morales-Sánchez, Gonzalo Castillo-Rojas, Yolanda López-Vidal, María Luisa Peralta-Pedrero, Fermín Jurado-Santa Cruz, Samuel Ponce de León-Rosales
BACKGROUND: Psoriasis is an autoimmune skin disease that may be associated with articular manifestations, and the most common clinical presentation is the variety "in plaques". In Mexico, in the Centro Dermatológico Pascua, it is the eighth leading cause of consultation. The aim of this study was to determine the diagnostic process of patients in a reference center for diseases of the skin. METHODS: Performing an analytical cross-sectional study that included 100 patients where the diagnostic process was questioned, clinimetric scales were applied and evaluated anthropometric...
May 2017: Gaceta Médica de México
https://www.readbyqxmd.com/read/28761839/a-real-world-study-to-assess-the-effectiveness-of-itolizumab-in-patients-with-chronic-plaque-psoriasis
#11
Anchala Parthasaradhi, Vinay Singh, S G Parasramani, Nishi Yadav, D S Krupashankar, Manish Soni, Rakesh Bansal
BACKGROUND: While clinical trial data on the efficacy of itolizumab in the management of psoriasis is relatively well documented, data on the effectiveness of this humanized IgG1 monoclonal antibody in real-world settings is sparse. AIMS: The current study assessed the effectiveness of itolizumab in real-world settings. MATERIALS AND METHODS: This study assessed psoriasis area severity index (PASI), dermatology quality of life index (DLQI), safety, and tolerability data from a registry of itolizumab maintained by Syngene International, Bangalore...
July 2017: Indian Dermatology Online Journal
https://www.readbyqxmd.com/read/28761838/topical-therapies-in-psoriasis
#12
REVIEW
R Torsekar, Manjyot M Gautam
Topical therapy as monotherapy is useful in psoriasis patients with mild disease. Topical agents are also used as adjuvant for moderate-to-severe disease who are being concurrently treated with either ultraviolet light or systemic medications. Emollients are useful adjuncts to the treatment of psoriasis. Use of older topical agents such as anthralin and coal tar has declined over the years. However, they are cheaper and can still be used for the treatment of difficult psoriasis refractory to conventional treatment...
July 2017: Indian Dermatology Online Journal
https://www.readbyqxmd.com/read/28761295/the-clinical-profile-of-patients-with-psoriasis-in-korea-a-nationwide-cross-sectional-study-epi-psode
#13
Hae Jun Song, Chul Jong Park, Tae Yoon Kim, Yong Beom Choe, Seok-Jong Lee, Nack In Kim, Jae We Cho, Jie Hyun Jeon, Min Soo Jang, Jai Il Youn, Myung Hwa Kim, Joonsoo Park, Ki Ho Kim, Byung Soo Kim, Sang Woong Youn, Joo-Heung Lee, Min-Geol Lee, Sung Ku Ahn, Young Ho Won, Seok Kweon Yun, Bong Seok Shin, Seong Jun Seo, Ji Yeoun Lee, Kwang Joong Kim, Young Suck Ro, Youngdoe Kim, Dae Young Yu, Jee-Ho Choi
BACKGROUND: Psoriasis is an immune-mediated, chronic inflammatory disease affecting multiple aspects of patients' lives. Its epidemiology varies regionally; however, nationwide epidemiologic data on psoriasis depicting profile of Korean patients has not been available to date. OBJECTIVE: To understand nationwide epidemiologic characteristics and clinical features of adult patients with psoriasis visited university hospitals in Korea. METHODS: This multicenter, non-interventional, cross-sectional study recruited 1,278 adult patients with psoriasis across 25 centers in Korea in 2013...
August 2017: Annals of Dermatology
https://www.readbyqxmd.com/read/28761289/gene-expression-analysis-of-inflammatory-cytokines-in-korean-psoriatic-patients
#14
Ji Hoon Chun, Young Hoon Yoon, Yong Beom Choe, Lae-Hyung Kang, Soon-Young Paik, Chul Jong Park
BACKGROUND: Although phenotypic heterogeneity of psoriasis is suggested by the alternate activation of either T-helper (Th)1-related or Th17-related cytokines, little is known about the mRNA levels of inflammatory cytokines. OBJECTIVE: To investigate whether there is differential expression of Th1-related and Th17-related inflammatory cytokine genes 1) between psoriatic patients and healthy controls, and 2) between patients with different psoriasis phenotypes. METHODS: Twenty-five patients with psoriasis (10 with guttate psoriasis and 15 with plaque psoriasis) and 5 healthy volunteers were enrolled in this study...
August 2017: Annals of Dermatology
https://www.readbyqxmd.com/read/28760056/cost-per-additional-responder-for-ixekizumab-and-other-fda-approved-biologics-in-moderate-to-severe-plaque-psoriasis
#15
Sarah Al Sawah, Shonda A Foster, Russel Burge, David Amato, Alexander Schacht, Baojin Zhu, Susanne Hartz, Craig Leonardi
BACKGROUND: Evidence of the cost-efficacy of ixekizumab for the treatment of moderate-to-severe plaque psoriasis (PsO) in the United States (US) is limited. OBJECTIVE: To estimate the number needed to treat (NNT) and monthly cost of achieving one additional Psoriasis Area and Severity Index (PASI) 75, 90, and 100 responder for ixekizumab and other Food and Drug Administration (FDA)-approved biologics in PsO. METHODS: A network meta-analysis estimated the probability of achieving PASI 75, 90, or 100 response during induction for each biologic...
August 1, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/28756988/tissue-hemostasis-is-shifted-toward-thrombogenesis-in-the-psoriatic-plaques
#16
Edyta Gębska, Agnieszka Sikora-Żydek, Marek Michalski, Edyta Reichman-Warmusz, Józef Kurek, Damian Dudek, Wiktor Skowron, Jerzy Jarząb, Romuald Wojnicz
BACKGROUND: Psoriasis is a common autoimmune disease of unknown etiology. Recently, much attention has been paid to evidence that a local hypercoagulable state is an important contributing factor to the development of inflammatory skin diseases. Thus, the aim of this study was to characterize the local hemostasis in the affected skin of patients with psoriasis. METHODS: Skin biopsies of psoriatic plaques were obtained from 73 consecutive patients (48M, 25F, average age 45 years) with at least a one year history of the disease...
July 15, 2017: Pathology, Research and Practice
https://www.readbyqxmd.com/read/28755394/clinical-similarity-of-the-biosimilar-abp%C3%A2-501-compared-with-adalimumab-after-single-transition-long-term-results-from-a-randomised-double-blind-52-week-phase-3-study-in-moderate-to-severe-plaque-psoriasis-patients
#17
K Papp, H Bachelez, A Costanzo, P Foley, M Gooderham, P Kaur, S Philipp, L Spelman, N Zhang, B Strober
BACKGROUND: ABP 501, an FDA- and EMA-approved biosimilar, is highly similar to adalimumab in structure, function, and pharmacokinetics. OBJECTIVE: Demonstrate similarity in efficacy, safety, and immunogenicity of ABP 501 versus adalimumab for moderate-to-severe plaque psoriasis. METHODS: Patients were randomised (1:1) to receive ABP 501 or adalimumab 40 mg every 2 weeks for 16 weeks. At Week 16, patients with ≥50% improvement from baseline in psoriasis area-and-severity index score (PASI) were eligible to continue to Week 52...
July 28, 2017: British Journal of Dermatology
https://www.readbyqxmd.com/read/28755058/novel-biologic-agents-targeting-interleukin-23-and-interleukin-17-for-moderate-to-severe-psoriasis
#18
REVIEW
Zeyu Chen, Yu Gong, Yuling Shi
Psoriasis is a common, chronic inflammatory skin disease and cannot be cured. The treatment of moderate-to-severe plaque psoriasis has been revolutionized with the development of biologic agents for nearly 20 years. Current studies show that interleukin-23 and interleukin-17 play remarkable roles in the pathogenesis of psoriasis. Interleukin-23 can sustain the differentiation and maintenance of T helper-17 lineage. Interleukin-17 can recruit and stimulate many cells, which play important parts in psoriasis through interacting with the interleukin-17 receptor...
July 28, 2017: Clinical Drug Investigation
https://www.readbyqxmd.com/read/28752373/skin-manifestations-of-rheumatoid-arthritis-juvenile-idiopathic-arthritis-and-spondyloarthritides
#19
REVIEW
Carolyn Jean Chua-Aguilera, Burkhard Möller, Nikhil Yawalkar
Extra-articular manifestations of rheumatoid arthritis, juvenile idiopathic arthritis, and various spondyloarthritides including psoriatic arthritis, ankylosing spondylitis, reactive arthritis, and inflammatory bowel disease-associated spondyloarthritis often involve the skin and may occur before or after diagnosis of these rheumatic diseases. Cutaneous manifestations encompass a wide range of reactions that may have a notable negative impact not only on the physical but especially on the emotional and psychosocial well-being of these patients...
July 27, 2017: Clinical Reviews in Allergy & Immunology
https://www.readbyqxmd.com/read/28748592/influence-of-narrowband-ultraviolet-b-phototherapy-on-serum-tumour-necrosis-factor-like-weak-inducer-of-apoptosis-tweak-in-patients-with-psoriasis
#20
H Myśliwiec, P Kiluk, P Myśliwiec, B Żelazowska-Rutkowska, A Baran, I Flisiak
Psoriasis is characterized by keratinocyte resistance to apoptosis. We recently demonstrated an increase in serum tumour necrosis factor-like weak inducer of apoptosis (TWEAK) in patients after topical treatment for psoriasis. We decided to verify whether narrowband ultraviolet B (NB-UVB) has a similar effect. Serum concentration of TWEAK was estimated in patients with exacerbated plaque psoriasis treated with NB-UVB. Baseline TWEAK levels were similar in patients with psoriasis and healthy controls, and Psoriasis Area and Severity Index (PASI) correlated inversely with TWEAK levels...
July 27, 2017: Clinical and Experimental Dermatology
keyword
keyword
82378
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"